A patient with lung adenocarcinoma and RET fusion treated with vandetanib

Journal of Thoracic Oncology

Volumn 8, Issue 5, 2013, Pages

  Gautschi, Oliver ^a   Zander, Thilo ^a   Keller, Franziska Aebersold ^a   Strobel, Klaus ^a   Hirschmann, Astrid ^a   Aebi, Stefan ^a   Diebold, Joachim ^a  

^a LUZERNER KANTONSSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOCETAXEL; FLUORODEOXYGLUCOSE; POLYCYCLIC AROMATIC HYDROCARBON; THYROID TRANSCRIPTION FACTOR 1; VANDETANIB;

ABDOMINAL PAIN; ADJUVANT THERAPY; ADULT; CANCER CHEMOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CORONARY STENT; FAMILY HISTORY; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HEART INFARCTION; HOSPITAL ADMISSION; HUMAN; HUMAN TISSUE; LOBECTOMY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LYMPH NODE BIOPSY; MALE; MEDIASTINUM LYMPH NODE; MULTIPLE CYCLE TREATMENT; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL (TOPIC); PORTAL VEIN THROMBOSIS; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; THROMBOEMBOLISM;

EID: 84876383602     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31828a4d07     Document Type: Article

References (5)

1. Wells SA Jr, Robinson BG, Gagel R F, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 2012;30:134-141.
2. Wang R, Hu H, Pan Y, et al. RET fusions defne a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. J Clin Oncol 2012;30:4352-4359.
3. Chao BH, Briesewitz R, Villalona-Calero MA. RET fusion genes in non-small-cell lung cancer. J Clin Oncol 2012;30:4439-4441.
4. Matsubara D, Kanai Y, Ishikawa S, et al. Identifcation of CCDC6-RET fusion in the human lung adenocarcinoma cell line, LC-2/ad. J Thorac Oncol. 2012;7(12):1872-6.
5. Wolff DJ, Bagg A, Cooley LD, et al.; Association for Molecular Pathology Clinical Practice Committee; American College of Medical Genetics Laboratory Quality Assurance Committee. Guidance for fuorescence in situ hybridization testing in hematologic disorders. J Mol Diagn 2007;9:134-143.